Alchemedicine patents new angiotensin AT1 receptor agonists
June 8, 2023
Alchemedicine Inc. has prepared and tested new angiotensin AT1 receptor (AGTR1) antagonists reported to be useful for the treatment of cancer, hypertension, glaucoma and renal disorders.